Being able to deliver the drug directly to the diseased cells will improve options for treating the disease. Some radioisotopes have already been approved to target cancer. When these isotopes change from one isotope to another during the processing process (for example, by radioactive decay), they release large amounts of energy. This makes it difficult to keep them in place near diseased cells or other targets. Researchers are currently testing methods of encapsulating isotopes in small pieces of biodegradable material that retain the isotopes at the treatment site. This ensures that their energy can kill cancer cells or other targets with little effect on surrounding cells. In this study, researchers show that these polymers successfully contain similar but non-radioactive metal atoms. This is an important step in providing medical isotopes using these polymers.
Scientists have previously shown that encapsulating a drug in small particles of a particular polymer called poly (lactic acid-glycolic acid) or PLGA can keep the drug in a particular state. cell In the body. Scientists have theorized that the radioactive medical isotopes contained in PLGA should do the same. PLGA also fits the human body. This reduces the risk that the body will reject these substances. PLGA also breaks down over time and leaves the body. These factors make PLGA an excellent potential tool for providing radioisotope therapies worthy of future research.
Some alpha radioisotopes approved for cancer treatment are “self-targeting.” One example is the bone cancer treatment radium-223, which behaves like calcium when delivered to the bone. However, it can be difficult to direct radium-223 to another type of tumor site. None of the standard methods of attaching radium-223 to a target molecule work. As a result, scientists are trying to capture radium-223 for delivery into molecular-sized nanoparticles of PLGA and other materials.Nanoparticles are potentially Isotope It is formed as radium-223 disintegrates away from the target site.
Further research will show whether encapsulating alpha-emitting radioisotopes can solve this delivery challenge.Testing PLGA with surrogate Metal ions It is promising because it can modify the surface of PLGA to target specific types of cancer cells. Since PLGA has a surrogate version of, it has also been shown to be promising in testing. Radioisotope, Shows that it can be captured within these types of nanoparticles. Since PLGA has already been used to encapsulate and release other types of organic compounds, studies may lead to the use of PLGA in anti-cancer agents if it can be replicated with radioisotopes. Researchers have used equivalent non-radioactive metal ions as a substitute for radioisotopes to provide evidence that the concept is sound and reduce the handling and disposal of radioactive material.
Through this study, research into the synthesis and characterization of radiotherapeutic surrogate encapsulated in PLGA nanoparticles was sponsored by a laboratory-led research and development program at Oak Ridge National Laboratory (ORNL). ORNL is a production / processing site within the US Department of Energy’s Department of Science isotope program.
Michael W. Ambrogio et al, Poly (lactic acid-co-glycolic acid) nanoparticles as a delivery system for improving the administration of radiotherapy antineoplastic agents, ACS Applied Nanomaterials (2020). DOI: 10.1021 / acsanm.0c02350
US Department of Energy
Quote: Better search for and destroy cancer by surrounding radiation-loaded particles (September 20, 2021).
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.
Encapsulation of radiation-loaded particles to better search for and destroy cancer
Source link Encapsulation of radiation-loaded particles to better search for and destroy cancer